Last week in New York, a room full of clinicians, investors, and policy people sat through a panel that quietly reset expectations for how psychedelic medicine actually reaches patients in the United States. Three federal officials — from the FDA, the VA, and ARPA-H — talked frankly about what the next twelve to twenty-four months really look like. The headline is sobering: even if MDMA-assisted therapy or psilocybin clears the regulatory finish line soon, the number of veterans who will actually get treated in year one may not even hit four digits.

If you're someone researching a psychedelic retreat because the clinical path feels impossibly far off — this is why. Let's unpack what was said, what it means for addiction and trauma treatment access, and where that leaves the rest of us who are watching plant medicines move through official channels at glacial speed.

What Federal Officials Actually Said About the Rollout

The panel featured Valentina Mantua from the FDA's regulatory science division, Andrew Gradison from the Department of Veterans Affairs, and Al Bugazia from ARPA-H. The moderator pushed them on the gap between “approved” and “available,” which, if you've been paying attention to this space, is the actual bottleneck nobody wants to talk about.

Gradison, who advises the Veterans Health Administration on psychedelics capacity, laid out the scale of the need in a way that's hard to shake. The VA covers roughly nine million veterans. About 6.4 million use VA healthcare regularly. Of those, somewhere around 2.1 million are living with PTSD, major depressive disorder, or treatment-resistant depression. Two point one million people. That's a mid-sized American city of veterans who, by the agency's own numbers, could potentially benefit from psychedelic-assisted therapy.

And the plan? Ten sites. Not named yet. Chosen because they already have clinical-trial experience with psychedelics. Gradison was careful to say the VA is “preparing to deploy these medicines as soon as they become commercially available,” and that in the rosiest scenario — approval landing in early next year — treatment could begin almost immediately. But he also admitted, more than once, that demand will crush supply. “It'll be a challenge in the first year to treat four digits' worth of patients,” he said. Four digits. Out of 2.1 million.

Why This Rollout Is So Painfully Slow

Here's the part that doesn't make headlines but matters most. Psychedelic-assisted therapy isn't like writing a prescription for an SSRI and sending someone home. Each session typically involves one or two trained therapists, a prepared setting, six to eight hours of monitored dosing, and multiple preparation and integration meetings before and after. It's labor-intensive in a way the modern healthcare system genuinely isn't built for.

Gradison used the phrase “safety-first mentality,” which sounds like boilerplate until you consider what it means operationally. You need trained clinicians. You need rooms that aren't typical clinic rooms. You need protocols for screening out contraindicated patients — anyone with certain cardiac issues, certain psychiatric histories, certain medication interactions. You need integration support, because without it, the breakthroughs people have during a session tend to dissolve back into old patterns within weeks.

Multiply that by ten sites across a country of 330 million people, and you start to see why “access” is the real story. Approval is the easy part. Building out an entire delivery infrastructure — therapists, physical space, insurance codes, safety protocols, aftercare — takes years. The VA is further along than almost any other system, and they're still telling us the first-year number might not break a thousand.

Ibogaine's “Uphill Battle” and the REMS Problem

The panel also touched on ibogaine, which has emerged as one of the most promising tools in addiction recovery — particularly for opioid use disorder — but which faces what one speaker frankly called an uphill battle in the United States. Ibogaine's cardiac risk profile makes it a regulatory nightmare. It can prolong the QT interval, which in rare cases triggers fatal arrhythmias. That's not a theoretical concern; it's the main reason the FDA hasn't moved on it despite decades of anecdotal and increasingly structured evidence from clinics in Mexico and elsewhere.

Any eventual US approval of ibogaine would almost certainly come with a Risk Evaluation and Mitigation Strategy — a REMS — which is a formal set of restrictions the FDA imposes on drugs with serious safety concerns. For ibogaine, that likely means cardiac monitoring, in-patient settings, exclusion of a wide range of patients on common medications, and significant infrastructure requirements. REMS programs are expensive and slow to build. They also tend to funnel treatment into a small number of specialized centers, which — again — creates a bottleneck between the people who need the medicine and the people who can actually get it.

None of this means ibogaine won't eventually reach US patients through legal channels. It just means the timeline is probably measured in many years, not months. For someone currently in active addiction, that's not a timeline. That's a sentence.

What This Means If You're Considering a Retreat Right Now

So where does this leave the person reading this because they're quietly weighing whether to book an ayahuasca retreat in Peru, an ibogaine program in Mexico, or a psilocybin container in Jamaica or the Netherlands? Honestly, it clarifies things.

The legal, insured, clinical pathway is coming — slowly, cautiously, and with real limits on who gets in. If you're a veteran with PTSD, you may eventually have access through the VA, but the odds of being in that first thousand are long. If you're outside the VA system, you'll be looking at private clinics, cash-pay, and whatever insurance ends up covering (which, initially, will be almost nothing).

Meanwhile, the international plant-medicine world — ayahuasca ceremonies in the Amazon, San Pedro work in the Andes, ibogaine programs in Tijuana and Costa Rica, psilocybin retreats where it's legal or decriminalized — continues to operate. It's not regulated the way a clinical setting is, which cuts both ways. The best retreats offer rigorous medical screening, experienced facilitators, serious integration support, and ceremonies rooted in traditions that long predate anyone's clinical trial. The worst are improvised, under-screened, and in some cases outright dangerous. The difference matters more than almost any other factor in whether an experience helps or harms you.

How to Evaluate a Retreat While the Clinical Path Catches Up

If you're going to pursue plant medicine or psychedelic healing outside the clinical system — and many thousands of people will, for perfectly understandable reasons — the quality of the container is everything. A few things to look for, from someone who's sat in a lot of ceremonies and interviewed a lot of facilitators:

• Real medical screening. A legitimate retreat asks about your medications, your cardiac history, your psychiatric history, your family mental health history. If they don't, that's a red flag the size of a billboard.
• Experienced facilitators with lineage or credentials. For ayahuasca, that often means curanderos trained in Shipibo, Shuar, or other Amazonian traditions. For ibogaine, that means medical staff on site with cardiac monitoring equipment. For psilocybin, that means facilitators trained in therapeutic containers, not just enthusiasts.
• Integration support. What happens after the ceremony is at least as important as what happens during it. A retreat that waves goodbye at the airport with no follow-up is leaving the most valuable part of the work on the table.
• Realistic claims. Nobody who knows what they're doing promises healing. The medicine shows you things; the work of integrating them is yours.
• Transparency about risk. Every psychedelic carries risk. Reputable retreats will tell you what those risks are, who shouldn't participate, and what their emergency protocols look like.

The Bigger Picture

The federal panel in New York made something clear that the enthusiasm of the past few years has sometimes obscured: regulatory approval is a starting line, not a finish line. The VA, with its specific mission and vast resources, is one of the few institutions actually building the infrastructure to deliver these treatments at any scale. And even they are telling us to manage expectations.

That's not a reason for despair. It's a reason for clear-eyed decision-making. The people who end up getting the most out of plant medicine — whether in a future clinical setting or in a current retreat context — tend to be the ones who approached it carefully, prepared properly, chose their container with discernment, and did the slow work of integration afterward. The medicine doesn't do the work for you. It opens a door. Walking through it is still your job.

If any of this has sharpened your thinking about what you might actually want to pursue, a range of carefully vetted ayahuasca, ibogaine, and psilocybin retreats can be browsed on our marketplace here. Take your time with the decision. The ceremonies will still be there next month.